SCHEMBL6741449

SCHEMBL6741449

CCOC(=O)C(CCSc1ccccc1)(NC(=O)c1ccccc1)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
RECQL P46063 2/20 0.48
ATM Q13315 2/20 0.47
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPK1 P28482 2/20 0.46
KMT2A Q03164 3/20 0.44
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 1/20 0.43
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6743871 0.83 NPC1 (0.56) NPC1RAB9ASMN1; SMN2RECQLALDH1A1
SCHEMBL621763 0.79 ALDH1A1 (0.52) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL5855727 0.79 ATM (0.54) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL5428506 0.78 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2RECQLALDH1A1
SCHEMBL18196123 0.78 MAPK1 (0.48) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL5856049 0.78 ATM (0.53) RECQLATMALDH1A1MAPK1KMT2A
SCHEMBL5855740 0.76 ATM (0.49) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL5855580 0.76 ATM (0.49) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL5856202 0.76 ATM (0.49) NPC1RAB9ASMN1; SMN2RECQLATM
SCHEMBL18196138 0.74 ATM (0.44) NPC1RAB9ASMN1; SMN2RECQLATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed
EP-1212302-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-06-12 EP disclosed
WO-2001019796-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE NPC1 45/4885RAB9A 401/4885SMN1; SMN2 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.